Stockreport

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivot [Read more]